A 2024 peer-reviewed study published in PubMed found that health claims appeared on 86.2% of supplement labels analyzed, but only 10.7% were compliant with authorized regulatory standards. The most common failure: claims derived from ingredient research that did not match the actual study conditions.
Ingredient-level claims are marketing statements built on research about a specific compound, where the studied ingredient may not match the final product in dose, format, formulation, or target population. The FTC requires that advertisers evaluate dose comparability, ingredient match, administration method, and population relevance before extrapolating from ingredient research to product claims. When those factors diverge, the claim requires adjustment.
Ingredient research and product claims exist at different levels of the evidence hierarchy. A study on an isolated ingredient produces findings specific to that ingredient at a specific dose, in a specific format, tested in a specific population. A product claim describes what a consumer using the finished product can expect.
Regulators and consumers both interpret ingredient-based marketing language as product-specific. When a label says "formulated with clinically studied ingredient X," consumers read it as "this product delivers the benefit that study showed." The FTC's guidance makes this interpretation explicit: a "clinically tested ingredient" claim "implies not only that the ingredient has a benefit but also that the product containing the ingredient confers that benefit."
The principle that governs this area is direct: the closer the match between research conditions and product formulation, the stronger the claim foundation. Four specific differences break that connection, creating claims the evidence cannot support.
An ingredient-level claim is a statement about what a specific compound has been shown to do in research, without asserting that the specific product delivers the same outcome.
Appropriate use cases:
What ingredient-level claims cannot do: they cannot imply that the finished product, as the consumer uses it, delivers the same outcome the study demonstrated. When the product formulation differs from the study conditions in dose, format, or combination, that implication becomes unsupported.
A product-level claim is a statement about what the actual product a consumer purchases does. It requires evidence connected to the final formulation, at the dose delivered by the product, through the delivery method the product uses, tested in a population comparable to the intended consumer.
Product-level claims require the strongest match between evidence and product. When that match exists, the claim is on solid ground. When it does not, product-level claim language applied to ingredient-level evidence is the most common form of substantiation overclaiming.
The wording transition from ingredient support to product guarantee happens in small steps. "Contains [ingredient], which has been clinically studied to improve X" is an ingredient claim with appropriate scope. "Clinically proven to improve X" as a product claim without product-level evidence is not. The words look similar. The compliance implications differ substantially.
For a practical look at how to build the full substantiation record behind product claims, our guide on how to build science-backed product claims covers the step-by-step process that connects evidence to approved claim language.
Dose is the most quantifiable gap between ingredient research and product claims, and one of the most frequently overlooked.
A clinical study testing 500mg per day of an ingredient produces evidence for 500mg per day. A product delivering 100mg of the same ingredient is delivering one-fifth of the studied dose. The original study does not support the claim that the product, at its actual dose, delivers the same outcome.
What this means practically:
The dose question is always worth asking before any ingredient claim is drafted. How much does the product actually deliver per serving, and does that match what was tested?
Bioavailability, the proportion of a substance that enters circulation and reaches the site of action, varies significantly by delivery format. An ingredient studied in a capsule does not behave identically when delivered in a beverage, a gummy, a powder, or a topical application.
A 2023 peer-reviewed analysis of curcumin formulations published in PubMed found that bioavailability varied dramatically across formulation types, including micelles, nanoparticles, and standard oral preparations, demonstrating that the same ingredient at the same dose can behave very differently depending on how it is formulated.
Format-specific factors that affect evidence transferability:
A study conducted on an oral capsule form of an ingredient supports claims for oral capsule products. It does not support topical claims, transdermal claims, or inhaled product claims without format-specific research to close the gap.
Finished products rarely contain a single active ingredient at the studied dose in isolation. They contain combinations, excipients, stabilizers, flavoring agents, and other compounds that can affect how the key ingredient performs.
The FTC's guidance addresses this directly in its four-question checklist: "Does the advertised product contain additional ingredients that might alter the effect of the ingredient in the study?" Additional ingredients can:
When a product contains multiple active ingredients and research exists only for one of them in isolation, the research cannot directly support claims about the combined formula's performance. The combination may perform better, worse, or differently. Without combination-specific research, that is unknown.
For context on how multi-ingredient formulations affect label compliance broadly, our guide on regulatory compliance in FMCG packaging covers the category-specific considerations.
The study population defines who the evidence applies to. A study conducted in adults over 60 with mild cognitive decline produces evidence for that specific group. Applying it to a general adult marketing claim requires additional research or explicit qualification.
Population matching factors to evaluate:
The practical test: can you describe the study population in two sentences, and does that description match your target consumer? If the answer to the second part is no, the evidence scope is narrower than the intended claim.
Example 1: Ingredient study extrapolated to a product guarantee
A study shows that a specific botanical ingredient significantly improved a measured sleep-onset outcome in a 12-week RCT. The product contains this ingredient, along with several other compounds, and the marketing claims: "Clinically proven to improve sleep quality."
What went wrong: The study measured one specific sleep outcome in a controlled population. The product is a multi-ingredient formula. No product-level clinical research exists for the final formulation.
Adjusted claim: "Contains [ingredient], shown in a clinical study to support healthy sleep onset." This accurately reflects the ingredient evidence without implying finished product clinical proof.
Example 2: Higher study dose than product delivers
A clinical study demonstrates a significant effect using 800mg per day. The product contains 200mg per serving. The marketing claims: "Shown to support healthy X levels."
What went wrong: The claim implies that the product dose produces the studied outcome when the product delivers only one-quarter of the studied dose.
Adjusted claim: "Contains [ingredient], which has been studied for its role in supporting healthy X levels." This preserves the ingredient connection without implying that the product dose delivers the studied outcome.
Example 3: Different delivery format
Research on an ingredient's effects was conducted using a standardized oral extract. The product uses a powder format with a different extraction process. The marketing claims: "Clinically studied for X."
What went wrong: The claim implies clinical evidence applies to the specific product when the product's format and extraction differ from the research conditions.
Adjusted claim: "Contains [ingredient extract], an ingredient with a history of research into its role in X." This keeps the educational positioning without claiming research equivalence the formulation does not support.
Ingredient research is genuinely valuable in the claim development process. It establishes scientific plausibility, informs formulation decisions, and supports educational content that builds consumer understanding. What it cannot do is substitute for finished product evidence when the product conditions differ materially from the study conditions.
The practical standard is alignment: the closer the match between what was studied and what the consumer is using, the more directly the research can support the claim. Ingredient claims are appropriate for ingredient evidence. Product claims require product-level evidence, or at minimum, a transparent, documented evaluation of why the ingredient evidence reasonably extends to the finished product.
For each claim in development, work through the four differences above: dose, delivery format, formulation, and population. Document where the evidence matches the product and where it does not. The claim language should reflect the actual match, not the desired match.
Eliminating the gap between ingredient studies and compliant product claims shouldn't slow down your launch cycles. Try GetGenAI now to instantly evaluate dose comparability, detect format mismatches, and build fully compliant marketing claims.
Can a brand reference ingredient research if its product contains a lower dose than the study?
Yes, with appropriate qualification. The claim should reflect the ingredient evidence accurately without implying that the lower product dose delivers the same outcome as the studied dose. Language like "contains [ingredient], which has been studied at doses of [X] for its role in Y" accurately communicates the evidence without suggesting dose equivalence. If dose-response research exists showing efficacy across a range that includes the product dose, that evidence strengthens the connection.
What type of scientific evidence is strongest for supporting a finished product claim?
A randomized controlled trial conducted on the finished product itself, at the actual product dose, in a population comparable to the intended consumer, is the strongest basis for direct product efficacy claims. The FTC's 2022 Health Products Compliance Guidance states that "as a general matter, substantiation of health-related benefits will need to be in the form of randomized, controlled human clinical testing." Ingredient studies can support ingredient-level claims but require additional evaluation before supporting finished product claims.
How should brands handle claims when multiple ingredients contribute to the same benefit?
When multiple ingredients in a formula are each supported by their own ingredient-level research for the same benefit, and no combination product study exists, the claims should reflect the individual ingredient evidence rather than implying a combined product-level proof. Language like "formulated with [ingredient A] and [ingredient B], each studied for their role in supporting X" is more accurate than a combined product efficacy claim. If combination-specific research is conducted and the product formula matches the study conditions, stronger product-level language becomes supportable.
Get intels on brand, platform, and regulatory changes, distilled by our compliance team
